Niagen Bioscience (NAGE)

Profile

Full Name

Niagen Bioscience, Inc.

Ticker Symbol

NAGE

Exchange

NASDAQ

Country

United States

IPO

June 24, 2015

Indexes

Not included

Employees

104

Key Details

Price

$13.88(-1.84%)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$99.60M(+19.18% YoY)

Annual EPS

$0.11(+257.14% YoY)

Next earnings date

Aug 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
See Full Chart & Historical Data

Analyst ratings

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

May 27, 25 Canaccord Genuity
Buy
Apr 8, 25 HC Wainwright & Co.
Buy
Mar 31, 25 HC Wainwright & Co.
Buy
Mar 17, 25 HC Wainwright & Co.
Buy
Mar 10, 25 HC Wainwright & Co.
Buy
Mar 5, 25 Ladenburg Thalmann
Buy
Nov 6, 24 Roth MKM
Buy
Nov 4, 24 HC Wainwright & Co.
Buy

Institutional Ownership

  • What is the ticker symbol for Niagen Bioscience?
  • Does Niagen Bioscience pay dividends?
  • What sector is Niagen Bioscience in?
  • What industry is Niagen Bioscience in?
  • What country is Niagen Bioscience based in?
  • When did Niagen Bioscience go public?
  • Is Niagen Bioscience in the S&P 500?
  • Is Niagen Bioscience in the NASDAQ 100?
  • Is Niagen Bioscience in the Dow Jones?
  • When was Niagen Bioscience's last earnings report?
  • When does Niagen Bioscience report earnings?
  • Should I buy Niagen Bioscience stock now?

What is the ticker symbol for Niagen Bioscience?

The ticker symbol for Niagen Bioscience is NASDAQ:NAGE

Does Niagen Bioscience pay dividends?

No, Niagen Bioscience does not pay dividends

What sector is Niagen Bioscience in?

Niagen Bioscience is in the Healthcare sector

What industry is Niagen Bioscience in?

Niagen Bioscience is in the Biotechnology industry

What country is Niagen Bioscience based in?

Niagen Bioscience is headquartered in United States

When did Niagen Bioscience go public?

Niagen Bioscience's initial public offering (IPO) was on June 24, 2015

Is Niagen Bioscience in the S&P 500?

No, Niagen Bioscience is not included in the S&P 500 index

Is Niagen Bioscience in the NASDAQ 100?

No, Niagen Bioscience is not included in the NASDAQ 100 index

Is Niagen Bioscience in the Dow Jones?

No, Niagen Bioscience is not included in the Dow Jones index

When was Niagen Bioscience's last earnings report?

Niagen Bioscience's most recent earnings report was on May 7, 2025

When does Niagen Bioscience report earnings?

The next expected earnings date for Niagen Bioscience is Aug 7, 2025

Should I buy Niagen Bioscience stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page